Therefore, until now, breast cancer patients who have a low-expressing level of HER2 have been categorised as HER2-negative in terms of treatment decisions and receive routine treatment based on the expression of hormone receptors and other targeted biomarkers (Schettini et al., 2021b). The gene discussed is ERBB2; the disease is breast carcinoma.